Ayush Ministry Issues Covid-19 Guidelines For Ayurveda And Unani Practitioners

Mumbai, 28 April 2021: The Union Ministry of Ayush has released revised guidelines for Ayurveda and Unani practitioners for Covid-19 patients in home isolation and Ayurveda and Unani preventive measures for self-care.

“It is aimed to increase awareness among the citizens regarding the effective home care solutions and recommended Ayush practices, to help them to enhance their immunity along with standard guideline for Ayurveda & Unani practitioners for management of prophylactic, asymptomatic and mild cases of Covid-19 during home isolation,” the ministry said.

These guidelines and advisories were developed through an extensive consultative process by the empowered committee within the interdisciplinary Ayush Research and Development Task Force setup by Union Ministry of Ayush.

The ministry said the Project Monitoring Unit for Covid-19 Studies, Central Council for Research in Ayurvedic Sciences (CCRAS), Central Council for Research in Unani Medicine (CCRUM), All India Institute of Ayurveda (AIIA) and National Medicinal Plant Board (NMPB) of this Ministry worked on formulating the advisories and guidelines.

The present guidelines and self-care measures provide clear guidance to Ayurveda & Unani practitioners regarding treatment of Covid-19 patients in different conditions of infection. This brings in uniformity and consistency in the Ayush-based responses to the pandemic across the country. It also helps state/UT governments to plan and incorporate these solutions into the Covid-19 management activities being deployed on the ground. Furthermore, these measures and guidelines contribute to the mainstreaming of Ayush solutions for the management of Covid-19, and will be immensely beneficial to the public since these solutions are easily accessible and will help to alleviate the hardships brought in by the pandemic.

The Ayush ministry issued an advisory on January 29, 2020 on how to protect oneself from Covid-19 and how to stay healthy. In this context, the ministry has also promoted the use of ready-made formulation like AyushKwath (Ayurveda) which is a simple admixture of four herbal ingredients which are well known in India and outside India for their immunomodulatory and anti-viral activities along with several other health benefits.

It added that keeping a note on the present public health challenges due to the second wave of Covid-19 pandemic, there is a requirement to urgently disseminate information about the guidelines for Ayurveda and Unani practitioners for the management of Covid-19 patients during home isolation.

“The effective evidence-based Ayurveda and Unani formulations/measures such as Ayush-64, Ashwagandha tablets, etc. have been included for the management of asymptomatic and mild cases of Covid-19 during home isolation,” it said.

  • Related Posts

    • Pharma
    • June 25, 2025
    • 75 views
    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    A major face-off is expected in India’s growing anti-obesity treatment market, as Danish pharma giant Novo Nordisk rolled out its blockbuster weight-loss drug Wegovy on Tuesday, just a month after…

    • Pharma
    • June 25, 2025
    • 101 views
    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Hyderabad:  Aurobindo Pharma Ltd wholly owned step-down subsidiary CuraTeQ Biologics has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India